Byakangelicol

CAS No. 26091-79-2

Byakangelicol( —— )

Catalog No. M18325 CAS No. 26091-79-2

Byakangelicol may inhibit P-gp expressed at the BBB even under in vivo conditions.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 146 In Stock
10MG 214 In Stock
25MG 353 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Byakangelicol
  • Note
    Research use only, not for human use.
  • Brief Description
    Byakangelicol may inhibit P-gp expressed at the BBB even under in vivo conditions.
  • Description
    Byakangelicol may inhibit P-gp expressed at the BBB even under in vivo conditions. Byakangelicol can inhibit IL-1beta-induced PGE2 release in A549 cells; this inhibition may be mediated by suppression of COX-2 expression and the activity of COX-2 enzyme, thus it may have therapeutic potential as an anti-inflammatory drug on airway inflammation.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    ERK
  • Recptor
    COX-2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    26091-79-2
  • Formula Weight
    316.3
  • Molecular Formula
    C17H16O6
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (158.07 mM)
  • SMILES
    CC1(C(O1)COC2=C3C(=C(C4=C2OC(=O)C=C4)OC)C=CO3)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • SMI-4a

    TCS-PIM-1-4a, a Pim inhibitor, blocks mTORC1 activity through activation of AMPK and kills a wide range of both myeloid and lymphoid cell lines (IC50=0.8-40 μM).

  • Patritumab

    Patritumab (U3-1287) is an anti-HER3 monoclonal antibody with potential antitumor activity and inhibits phosphorylation of EGFR, HER2, HER3, ERK, and AKT.Patritumab promotes apoptosis and inhibits proliferation in non-small cell lung cancer.

  • GSK2656157

    GSK2656157 is an ATP-competitive and highly selective inhibitor of PERK with IC50 of 0.9 nM in a cell-free assay.